Literature DB >> 1629407

Volume of pituitary macroadenomas: assessment by MRI.

P Lundin1, F Pedersen.   

Abstract

A phantom study was performed to assess the accuracy of MRI in volume determination of pituitary macroadenomas, using the summation of areas technique. Five phantoms, 3-4 cm in diameter, simulating pituitary macroadenomas of various shapes, were evaluated. The volume could adequately and reproducibly be determined, regardless of minor rotational variations of the phantom position. Using a three-dimensional SE sequence with 2.5 mm slices, the error was independent of the shape of the phantom and did not differ significantly from zero (less than 5%); this sequence was found to be the best of those tested. The coefficient of variation between examinations with different tilts was 2%. In a clinical part, the volume of pituitary macroadenomas was determined with the same technique on coronal two-dimensional 5 mm images and was used as a "gold standard" to which the largest transverse, sagittal, vertical, and oblique diameters, a central tumor area, and the product of the three orthogonal diameters were correlated. In interpatient comparisons the largest diameter was found to be useful, but only as a rough measure of the tumor size. The formula 0.5 x width x length x height provided a fairly adequate estimation of the tumor volume, except in the largest tumors. In intrapatient comparisons during bromocriptine treatment, the height was found to be the best of the diameters, but the central tumor area or the product of the orthogonal diameters was preferable.

Entities:  

Mesh:

Year:  1992        PMID: 1629407     DOI: 10.1097/00004728-199207000-00004

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  36 in total

1.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease.

Authors:  Kristin Huntoon; Tianxia Wu; J Bradley Elder; John A Butman; Emily Y Chew; W Marston Linehan; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2015-10-30       Impact factor: 5.115

3.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

4.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

5.  Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.

Authors:  Bahattin Tanrıkulu; Ayça Erşen Danyeli; M Memet Özek
Journal:  Childs Nerv Syst       Date:  2020-02-05       Impact factor: 1.475

6.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

7.  Long-term outcome of multimodal therapy for giant prolactinomas.

Authors:  Paula Andujar-Plata; Rocio Villar-Taibo; Maria Dolores Ballesteros-Pomar; Alfonso Vidal-Casariego; Begoña Pérez-Corral; Jose Manuel Cabezas-Agrícola; Paula Álvarez-Vázquez; Ramón Serramito; Ignacio Bernabeu
Journal:  Endocrine       Date:  2016-10-04       Impact factor: 3.633

8.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.

Authors:  Hai Yan Huang; Shao Jian Lin; Wei Guo Zhao; Zhe Bao Wu
Journal:  Metab Brain Dis       Date:  2018-03-15       Impact factor: 3.584

10.  Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.

Authors:  Russell R Lonser; John A Butman; Kristin Huntoon; Ashok R Asthagiri; Tianxia Wu; Kamran D Bakhtian; Emily Y Chew; Zhengping Zhuang; W Marston Linehan; Edward H Oldfield
Journal:  J Neurosurg       Date:  2014-02-28       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.